earnings
confidence high
sentiment positive
materiality 0.70
Nuwellis Q3 revenue $2.4M, net income $2.4M; CMS reimbursement up 297%
Nuwellis, Inc.
2024-Q3 EPS reported
-$14.99
revenue$6,418,000
- Revenue $2.4M, down 2% YoY; pediatrics revenue grew 28% YoY.
- Gross margin 70% vs 57.3% YoY; operating expenses down 30% YoY.
- Net income attributable to common $2.4M ($1.74/share) vs loss $3.4M; includes $3.9M warrant liability benefit.
- CMS increased Aquadex facility fee reimbursement 297% to $1,639/day, effective Jan 1, 2025.
- Cash $1.9M, no debt; $5.1M gross proceeds from November warrant exercise.